Kodiak Sciences Inc. reported a net loss of $58.2 million for the first quarter of 2026, a slight increase from the $57.5 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were $59.8 million, compared to $59.1 million in the prior year. Research and development expenses rose to $48.5 million, up from $43.6 million, primarily due to increased costs associated with clinical trials for its product candidates. General and administrative expenses decreased to $11.2 million from $15.4 million, reflecting lower stock compensation expenses and reduced facility costs following a sublease agreement.

As of March 31, 2026, Kodiak's cash and cash equivalents stood at $169.5 million, down from $209.9 million at the end of 2025. The company’s total assets decreased to $306.0 million from $351.5 million, while total liabilities remained relatively stable at $193.9 million. The accumulated deficit increased to $1.6 billion, highlighting the ongoing financial challenges faced by the company as it continues to invest heavily in research and development without generating product revenue.

Strategically, Kodiak is advancing its clinical pipeline, which includes three late-stage product candidates: Zenkuda (tarcocimab), KSI-501, and KSI-101. Zenkuda has completed four Phase 3 pivotal studies and is currently in the DAYBREAK study for wet AMD, with topline results expected in the third quarter of 2026. KSI-501 and KSI-101 are also progressing through their respective Phase 3 trials, with KSI-101 targeting macular edema secondary to inflammation. The company is also developing dual cytokine-targeting bispecific antibody programs and enhancing its digital health platform through the VETi program.

Looking ahead, Kodiak anticipates continued operating losses and negative cash flows as it seeks to bring its product candidates to market. The company plans to raise additional capital to support its operations and research activities, although it acknowledges the uncertainty surrounding future financing. Kodiak's ability to achieve profitability will depend on the successful development and commercialization of its product candidates, as well as the overall market conditions and regulatory approvals.

About Kodiak Sciences Inc.

Kodiak Sciences Inc. develops innovative retinal therapies using its Antibody Biopolymer Conjugate (ABC) Platform. Its core focus is on creating biologics for major retinal diseases like AMD, diabetic retinopathy, and retinal vein occlusion. The company’s key products include tarcocimab, KSI-501, and KSI-101, targeting inflammation and vascular issues. Kodiak emphasizes high efficacy, durability, and tailored delivery, aiming to improve patient outcomes and reduce treatment burdens in ophthalmology markets.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.